Ubs Group Ag Virpax Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.24 - $0.82 $1,559 - $5,328	6,498 Added 5506.78%	6,616 $2,000
Q3 2023 Nov 09, 2023	BUY	$0.76 - $1.1 $89 - $129	118 New	118 $0
Q4 2022 Feb 08, 2023	BUY	$0.62 - $12.0 $3,442 - $66,636	5,553 Added 88.2%	11,849 $7,000
Q3 2022 Nov 10, 2022	BUY	$1.15 - $11.9 $7,240 - $74,922	6,296 New	6,296 $7,000
Q1 2022 May 16, 2022	SELL	$1.86 - $3.61 $21,176 - $41,099	-11,385 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$3.19 - $4.89 $36,318 - $55,672	11,385 New	11,385 $39,000
Q3 2021 Nov 15, 2021	SELL	$4.14 - $22.9 $16,319 - $90,271	-3,942 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$3.84 - $6.0 $3,694 - $5,772	962 Added 32.28%	3,942 $18,000
Q1 2021 May 12, 2021	BUY	$4.39 - $6.53 $13,082 - $19,459	2,980 New	2,980 $14,000

Ticker VRPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,714,600
Market Cap $7.97M
Description
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical no...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.